Skip Nav Destination

First Edition

Research Article June 9 2025

A Phase 1 Study of IO-202, an Anti-LILRB4 Antibody, in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Research Article June 9 2025

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: A Danish population-based study

Trine Trab,Iman Chanchiri,Ahmed Ludvigsen Al-Mashhadi,Emma Berggreen Dall,Stine Rasch,Mette Johansen,Simon Husby,Mikkel Runason Simonsen,Michael Roost Clausen,Thomas Stauffer Larsen,Jacob Haaber Christensen,Robert Schou Pedersen,Mikael Frederiksen,Mats Jerkeman,Christian Bjørn Poulsen,Laura Mors Haunstrup,Peter Brown,Tarec Christoffer El-Galaly,Kirsten Grønbæk

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article June 9 2025

Correlates of Organ Damage in Advanced Systemic Mastocytosis Patients Enrolled in Clinical Trials of Avapritinib

Emily C. Liang,Cecelia Perkins,Rong Lu,Hongliang Shi,Saša Dimitrijević,Justin Abuel,Cheryl Langford,Parveen Abidi,Lenn Fechter,William Shomali,Jason Gotlib

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article June 3 2025

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Tadeusz Kubicki,Benjamin A Derman,Jennifer H Cooperrider,Anna Puła,David Barnidge,Dominik Dytfeld,Ken Jiang,Andrzej J Jakubowiak

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Brief Report June 3 2025

Beat AML genetic risk stratification model in an older VEN/HMA-treated AML patient cohort

Fieke W. Hoff,Ashley O. Yocum,Uma M. Borate,Alice S. Mims,John C. Byrd,Yazan F. Madanat

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article June 3 2025

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML

Adam Y. Lin,Jonathan S. Rink,Eva Yang,Sara Small,Jessica J. Gerber,Taylor J Zak,Jessica Altman,Yasmin Abaza,Leonidas C. Platanias,Leo I Gordon,C. Shad Thaxton

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article June 3 2025

V-FAST: A phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

Vinod A. Pullarkat,Mark Levis,James McCloskey,Gabriel N. Mannis,Stephen A. Strickland,Amir T. Fathi,Tara L. Lin,Vijaya R. Bhatt,Thuva Vanniyasingam,Divya Chakravarthy,Yana Lutska,Stefan Faderl,Ronald S. Cheung,Harry P. Erba

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 19 2025

An Antibody-Drug Conjugate Targeting VpreB1 for the Treatment of B-cell Acute Lymphoblastic Leukemia

Peter M. Gordon,Robin L. Williams,Jason Ostergaard,Keegan C. Lee,Hannah N. Bui,Joseph M. Muretta,Bridget S. Wilson,Thomas Beder,Claudia D. Baldus,Luke Lambert,Benjamin E. Deonovic,Timothy Singleton,Sarah K. Tasian,Stuart S. Winter

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 19 2025

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation

Madhavi D. Senagolage,Hunter Z. Blaylock,Saira Khan,Sarah J. Skuli,Martin P. Carroll,Megan E. McNerney

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 19 2025

PPARγ-induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in AML.

Kotoko Yamatani,Tatsuro Watanabe,Kaori Saito,Abdullah Khasawneh,Abhishek Maiti,Zhihong Zeng,Kala Hayes,Shinya Kimura,Courtney D. DiNardo,Xiaoping Su,Shuko Nojiri,Yasushi Okazaki,Michael Andreeff,Marina Konopleva,Yoko Tabe

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 19 2025

Outcomes and factors influencing survival in patients with diffuse large B cell lymphoma: a population-based analysis

Inna Y Gong,Michael Crump,Anca Prica,Andrew Calzavara,Ning Liu,Tiana Kordbacheh,Danielle Rodin,David Hodgson,Lee Mozessohn,Matthew Cheung,John Kuruvilla

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 19 2025

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

Rose Laflamme,Véronique Lisi,Josée Hébert,Guy Sauvageau,Sébastien Lemieux,Vincent-Philippe Lavallée,Guillaume Lettre

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 12 2025

Real world performance of the CALGB 10403 regimen in young adults in the United States

Brandon DaSilva,Alicia Darwin,Amy Zhang,Rutu D. Vyas,Kathryn Russell,Jason S. Gilbert,Virginia Tan,Susan Feldt,Hannah Johnston,Emily C Liang,Adam S. DuVall,Michaela Liedtke,Wendy Stock,Ryan D. Cassaday,Marc Schwartz,Jessica T. Leonard,Lori S. Muffly,Marlise R. Luskin

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 11 2025

Gut Faecalibacterium abundance in patients with plasma cell disorders is associated with survival after autologous HSCT

Erin A. Dean,Arkaprava Roy,Rick Y. Lin,Raad Z. Gharaibeh,Derek M. Li,Josee Gauthier,Christian Jobin,John R. Wingard

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 11 2025

A Comparative Assessment of Molecular-Based Prognostic Models in CMML

Luis E. Aguirre,Najla Al Ali,Somedeb Ball,Akriti G. Jain,David Sallman,Andrew Kuykendall,Alison R. Walker,Kendra Sweet,Jeffrey E. Lancet,Eric Padron,Rami S. Komrokji

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 11 2025

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 11 2025

Tagraxofusp, a CD123-Targeted Therapy, for Chronic Myelomonocytic Leukemia: Final Results of a Phase 1/2 Study

Mrinal M. Patnaik,Haris Ali,Eunice S. Wang,Abdulraheem Yacoub,James M. Foran,Vikas Gupta,Gary J. Schiller,Don Ambrose Stevens,Moshe Talpaz,Sarah Wall,Terra L Lasho,Abhishek A. Mangaonkar,Talha Badar,Ross Lindsay,Antonio Galleu,Ira Gupta,Naveen Pemmaraju,Guillermo Garcia-Manero

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article May 11 2025

Prognostic impact of Extranodal Disease on PET/CT in Follicular Lymphoma: Results from a Validation Study with ECOG 2408

Frederique St-Pierre,Stephen M. Broski,Zequn Sun,Masha Kocherginsky,Betsy Laplant,Matthew J. Maurer,Andrew Quon,Lucia Baratto,Hatice Savas,Lale Kostakoglu,Jane N. Winter,Thomas E. Witzig,Brad Kahl,Andrew M. Evens,Leo I. Gordon

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Brief Report May 11 2025

Temporal clonal relatedness between myeloid neoplasm and nodal T follicular helper cell lymphoma: a retrospective study

Mingfei Yan,Robert Stuver,Kai Shiang Lin,William T. Johnson,Steven M. Horwitz,Ahmet Dogan,Wenbin Xiao

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 25 2025

Activity of STAMP inhibitors in ABL2 rearranged Acute Lymphoblastic Leukemia is dependent on the Abl2 SH3 domain

Elias Lagonik,Elyse C. Page,John B. Bruning,Laura N. Eadie,Susan L. Heatley,Matthew Greenwood,Chun Y. Fong,Andrew S. Moore,David T. Yeung,Timothy P. Hughes,Deborah L. White

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 25 2025

Checkpoint immunotherapy is associated with preferential activation of tumor-antigen specific CD4⁺ T cells in MDS.

Elizabeth A. Griffiths,Pragya Srivastava,Eduardo Cortes Gomez,Junko Matsuzaki,Kunle Odunsi,Laura W. Dillon,Devdeep Mukherjee,Christopher S. Hourigan,Jacqueline Peng,Shovik Bandyopadhyay,Kai Tan,Kristopher M. Attwood,Joseph B. Kuechle,Prashant K. Singh,Jianmin Wang,Michael J. Nemeth

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 25 2025

The oral CDK9 inhibitor voruciclib combined with venetoclax in patients with relapsed/refractory acute myeloid leukemia

Yesid Alvarado-Valero,Rachel J. Cook,Shira N. Dinner,Michael Keng,Kebede H. Begna,Nathalie Javidi-Sharifi,Sameem Abedin,Monzr M. Al Malki,Vijaya Raj Bhatt,Prabhu Rajagopalan,Min Tang,Sandra E. Wiley,Richard G. Ghalie,Matthew S. Davids

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 25 2025

Targeting HASPIN kinase disrupts SR protein-mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

Mengdan Liu,Ming Yan,Amanda G. Davis,Samuel A. Stoner,Edward D. Ball,Dong-Er Zhang

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 16 2025

Outcomes at a Single Institution with MTR Induction and Consolidation in the Management of Primary CNS Lymphoma

Nikita K. Dave,Veronica Carvajal,Alex C. Watts,Jordan S. Carter,Michael Cook,Colin Thomas,Donald E. Tsai,Stephen J. Schuster,James N. Gerson,Stefan K. Barta,Jakub Svoboda,Elise A. Chong,Wei-Ting Hwang,Daniel J. Landsburg,Sunita D. Nasta

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 16 2025

Outcomes of Myeloablative Allogeneic Hematopoietic Cell Transplantation with Omidubicel vs Haploidentical and Unrelated Donor Sources

Chenyu Lin,Smitha Sivaraman,Gautam Sajeev,Yan Song,Chunyi Xu,Chujun He,James E. Signorovitch,Heayoung Shin,Xiao-Ying Tang,Mei-Jie Zhang,Linda J. Burns,Ronit Simantov,Mitchell E. Horwitz

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 16 2025

Olfactory Receptors as Tumor Suppressors in Cutaneous T-Cell Lymphoma via p38γ Pathway Modulation

Xu Hannah Zhang,Hongzhi Li,Jack Hsiang,Ching-Hong Chen,Sangkil Nam,Henry Wong,Xiwei Wu,Weidong Hu,Jack Shively,Steven T. Rosen

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 4 2025

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma

Yuan Xiao Zhu,Soumya Dutta,Gregory J. Ahmann,Laura Bruins,Mariano Arribas,Xianfeng Chen,Abhigna Polikarpov,Jonathan Chapman,Issac Lopez,Marta Chesi,P. Leif Bergsagel,Abhishek Singharoy,Rafael Fonseca,Lisa M. Rimsza

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplementary data

Research Article April 3 2025

Quality of life, fatigue, depression, attention deficits and pain after childhood Langerhans cell histiocytosis

Malin Sveijer,Désirée Gavhed,Helena Hertzberg,Eric Zander,Jan-Inge Henter,Tatiana von Bahr Greenwood

View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

First Edition

A Phase 1 Study of IO-202, an Anti-LILRB4 Antibody, in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: A Danish population-based study

Correlates of Organ Damage in Advanced Systemic Mastocytosis Patients Enrolled in Clinical Trials of Avapritinib

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Beat AML genetic risk stratification model in an older VEN/HMA-treated AML patient cohort

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML

V-FAST: A phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

An Antibody-Drug Conjugate Targeting VpreB1 for the Treatment of B-cell Acute Lymphoblastic Leukemia

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation

PPARγ-induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in AML.

Outcomes and factors influencing survival in patients with diffuse large B cell lymphoma: a population-based analysis

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

Real world performance of the CALGB 10403 regimen in young adults in the United States

Gut Faecalibacterium abundance in patients with plasma cell disorders is associated with survival after autologous HSCT

A Comparative Assessment of Molecular-Based Prognostic Models in CMML

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

Tagraxofusp, a CD123-Targeted Therapy, for Chronic Myelomonocytic Leukemia: Final Results of a Phase 1/2 Study

Prognostic impact of Extranodal Disease on PET/CT in Follicular Lymphoma: Results from a Validation Study with ECOG 2408

Temporal clonal relatedness between myeloid neoplasm and nodal T follicular helper cell lymphoma: a retrospective study

Activity of STAMP inhibitors in ABL2 rearranged Acute Lymphoblastic Leukemia is dependent on the Abl2 SH3 domain

Checkpoint immunotherapy is associated with preferential activation of tumor-antigen specific CD4⁺ T cells in MDS.

The oral CDK9 inhibitor voruciclib combined with venetoclax in patients with relapsed/refractory acute myeloid leukemia

Targeting HASPIN kinase disrupts SR protein-mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

Outcomes at a Single Institution with MTR Induction and Consolidation in the Management of Primary CNS Lymphoma

Outcomes of Myeloablative Allogeneic Hematopoietic Cell Transplantation with Omidubicel vs Haploidentical and Unrelated Donor Sources

Olfactory Receptors as Tumor Suppressors in Cutaneous T-Cell Lymphoma via p38γ Pathway Modulation

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma

Quality of life, fatigue, depression, attention deficits and pain after childhood Langerhans cell histiocytosis

ASH Publications

American Society of Hematology

First Edition

A Phase 1 Study of IO-202, an Anti-LILRB4 Antibody, in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia Open Access

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: A Danish population-based study Open Access

Correlates of Organ Damage in Advanced Systemic Mastocytosis Patients Enrolled in Clinical Trials of Avapritinib Open Access

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma. Open Access

Beat AML genetic risk stratification model in an older VEN/HMA-treated AML patient cohort Open Access

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML Open Access

V-FAST: A phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML Open Access

An Antibody-Drug Conjugate Targeting VpreB1 for the Treatment of B-cell Acute Lymphoblastic Leukemia Open Access

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation Open Access

PPARγ-induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in AML. Open Access

Outcomes and factors influencing survival in patients with diffuse large B cell lymphoma: a population-based analysis Open Access

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls Open Access

Real world performance of the CALGB 10403 regimen in young adults in the United States Open Access

Gut Faecalibacterium abundance in patients with plasma cell disorders is associated with survival after autologous HSCT Open Access

A Comparative Assessment of Molecular-Based Prognostic Models in CMML Open Access

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia Open Access

Tagraxofusp, a CD123-Targeted Therapy, for Chronic Myelomonocytic Leukemia: Final Results of a Phase 1/2 Study Open Access

Prognostic impact of Extranodal Disease on PET/CT in Follicular Lymphoma: Results from a Validation Study with ECOG 2408 Open Access

Temporal clonal relatedness between myeloid neoplasm and nodal T follicular helper cell lymphoma: a retrospective study Open Access

Activity of STAMP inhibitors in ABL2 rearranged Acute Lymphoblastic Leukemia is dependent on the Abl2 SH3 domain Open Access

Checkpoint immunotherapy is associated with preferential activation of tumor-antigen specific CD4+ T cells in MDS. Open Access

The oral CDK9 inhibitor voruciclib combined with venetoclax in patients with relapsed/refractory acute myeloid leukemia Open Access

Targeting HASPIN kinase disrupts SR protein-mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML Open Access

Outcomes at a Single Institution with MTR Induction and Consolidation in the Management of Primary CNS Lymphoma Open Access

Outcomes of Myeloablative Allogeneic Hematopoietic Cell Transplantation with Omidubicel vs Haploidentical and Unrelated Donor Sources Open Access

Olfactory Receptors as Tumor Suppressors in Cutaneous T-Cell Lymphoma via p38γ Pathway Modulation Open Access

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma Open Access

Quality of life, fatigue, depression, attention deficits and pain after childhood Langerhans cell histiocytosis Open Access

ASH Publications

American Society of Hematology

A Phase 1 Study of IO-202, an Anti-LILRB4 Antibody, in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: A Danish population-based study

Correlates of Organ Damage in Advanced Systemic Mastocytosis Patients Enrolled in Clinical Trials of Avapritinib

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Beat AML genetic risk stratification model in an older VEN/HMA-treated AML patient cohort

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML

V-FAST: A phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

An Antibody-Drug Conjugate Targeting VpreB1 for the Treatment of B-cell Acute Lymphoblastic Leukemia

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation

PPARγ-induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in AML.

Outcomes and factors influencing survival in patients with diffuse large B cell lymphoma: a population-based analysis

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

Real world performance of the CALGB 10403 regimen in young adults in the United States

Gut Faecalibacterium abundance in patients with plasma cell disorders is associated with survival after autologous HSCT

A Comparative Assessment of Molecular-Based Prognostic Models in CMML

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

Tagraxofusp, a CD123-Targeted Therapy, for Chronic Myelomonocytic Leukemia: Final Results of a Phase 1/2 Study

Prognostic impact of Extranodal Disease on PET/CT in Follicular Lymphoma: Results from a Validation Study with ECOG 2408

Temporal clonal relatedness between myeloid neoplasm and nodal T follicular helper cell lymphoma: a retrospective study

Activity of STAMP inhibitors in ABL2 rearranged Acute Lymphoblastic Leukemia is dependent on the Abl2 SH3 domain

Checkpoint immunotherapy is associated with preferential activation of tumor-antigen specific CD4⁺ T cells in MDS.

The oral CDK9 inhibitor voruciclib combined with venetoclax in patients with relapsed/refractory acute myeloid leukemia

Targeting HASPIN kinase disrupts SR protein-mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

Outcomes at a Single Institution with MTR Induction and Consolidation in the Management of Primary CNS Lymphoma

Outcomes of Myeloablative Allogeneic Hematopoietic Cell Transplantation with Omidubicel vs Haploidentical and Unrelated Donor Sources

Olfactory Receptors as Tumor Suppressors in Cutaneous T-Cell Lymphoma via p38γ Pathway Modulation

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma

Quality of life, fatigue, depression, attention deficits and pain after childhood Langerhans cell histiocytosis